Literature DB >> 21293502

Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI.

Dale N Gerding1, Stuart Johnson.   

Abstract

Clostridium difficile infection (CDI) publications have advanced in 2010 at a pace paralleling the increased frequency and severity of clinical infection. Both toxins A and B are essential virulence factors, pcr diagnostic testing is rapid, sensitive and specific, and recurrent CDI can be prevented using monoclonal antibodies to toxins A and B.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21293502     DOI： 10.1038/nrgastro.2010.215

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  10 in total

Review 1.  Management of Clostridium difficile infection: thinking inside and outside the box.

Authors:  Dale N Gerding; Stuart Johnson
Journal:  Clin Infect Dis       Date:  2010-10-27       Impact factor: 9.079

2.  A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.

Authors:  Gerald W Tannock; Karen Munro; Corinda Taylor; Blair Lawley; Wayne Young; Brendan Byrne; Judy Emery; Thomas Louie
Journal:  Microbiology (Reading)       Date:  2010-08-19       Impact factor: 2.777

3.  Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay.

Authors:  S Johnson; S A Kent; K J O'Leary; M M Merrigan; S P Sambol; L R Peterson; D N Gerding
Journal:  Ann Intern Med       Date:  2001-09-18       Impact factor: 25.391

4.  Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches.

Authors:  Fred C Tenover; Susan Novak-Weekley; Christopher W Woods; Lance R Peterson; Thomas Davis; Paul Schreckenberger; Ferric C Fang; Andre Dascal; Dale N Gerding; Jim H Nomura; Richard V Goering; Thomas Akerlund; Alice S Weissfeld; Ellen Jo Baron; Edith Wong; Elizabeth M Marlowe; Joseph Whitmore; David H Persing
Journal:  J Clin Microbiol       Date:  2010-08-11       Impact factor: 5.948

5.  The role of toxin A and toxin B in Clostridium difficile infection.

Authors:  Sarah A Kuehne; Stephen T Cartman; John T Heap; Michelle L Kelly; Alan Cockayne; Nigel P Minton
Journal:  Nature       Date:  2010-09-15       Impact factor: 49.962

6.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

7.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Treatment with monoclonal antibodies against Clostridium difficile toxins.

Authors:  Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

9.  Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).

Authors:  Brett A Leav; Barbra Blair; Mark Leney; Michael Knauber; Courtney Reilly; Israel Lowy; Dale N Gerding; Ciarán P Kelly; Kia Katchar; Roger Baxter; Donna Ambrosino; Deborah Molrine
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

10.  Toxin B is essential for virulence of Clostridium difficile.

Authors:  Dena Lyras; Jennifer R O'Connor; Pauline M Howarth; Susan P Sambol; Glen P Carter; Tongted Phumoonna; Rachael Poon; Vicki Adams; Gayatri Vedantam; Stuart Johnson; Dale N Gerding; Julian I Rood
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962
  10 in total
  9 in total

1.  Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.

Authors:  Hon Wai Koon; David Q Shih; Tressia C Hing; Jun Hwan Yoo; Samantha Ho; Xinhua Chen; Ciarán P Kelly; Stephan R Targan; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

2.  Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile.

Authors:  Meena Sachdeva; Jennifer A Leeds
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

3.  Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.

Authors:  Hon Wai Koon; Samantha Ho; Tressia C Hing; Michelle Cheng; Xinhua Chen; Yoshi Ichikawa; Ciarán P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

4.  Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.

Authors:  Hans H Locher; Patrick Caspers; Thierry Bruyère; Susanne Schroeder; Philippe Pfaff; Andreja Knezevic; Wolfgang Keck; Daniel Ritz
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

5.  To study the contributing factors and outcomes of Clostridioides difficile infection in patients with solid tumors.

Authors:  Kamal Kant Sahu; Ajay Kumar Mishra; Vishal Jindal; Ahmad Daniyal Siddiqui; Susan V George
Journal:  Heliyon       Date:  2021-11-26

Review 6.  Clostridium difficile infection in patients with inflammatory bowel disease.

Authors:  Jacek Czepiel; Grażyna Biesiada; William Perucki; Tomasz Mach
Journal:  Prz Gastroenterol       Date:  2014-06-26

7.  The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection.

Authors:  Mária Džunková; Giuseppe D'Auria; Hua Xu; Jun Huang; Yinghua Duan; Andrés Moya; Ciarán P Kelly; Xinhua Chen
Journal:  Front Cell Infect Microbiol       Date:  2016-10-04       Impact factor: 5.293

8.  Evaluation of inpatients Clostridium difficile prevalence and risk factors in Cameroon.

Authors:  Ingrid Cécile Djuikoue; Ernest Tambo; Gildas Tazemda; Omer Njajou; Denise Makoudjou; Vanessa Sokeng; Morelle Wandji; Charlène Tomi; Aubain Nanfack; Audrey Dayomo; Suzie Lacmago; Falubert Tassadjo; Raissa Talla Sipowo; Caroline Kakam; Aicha Bibiane Djoko; Clement Nguedia Assob; Antoine Andremont; Frédéric Barbut
Journal:  Infect Dis Poverty       Date:  2020-08-31       Impact factor: 4.520

9.  Immunogenicity and Protection from Receptor-Binding Domains of Toxins as Potential Vaccine Candidates for Clostridium difficile.

Authors:  Deyan Luo; Xuechao Liu; Li Xing; Yakun Sun; Jie Huang; Liangyan Zhang; Jiajia Li; Hui Wang
Journal:  Vaccines (Basel)       Date:  2019-11-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.